Cancer Immunotherapy, TMB and Clinical Trial Matching

This week was the American Association for Cancer Research (AACR) annual meeting in Washington, DC. As we followed the event, we identified the 140-character anecdotes and quotes that shine a light on emerging trends in cancer research.

Cancer immunotherapy continues to be a hot topic. While the treatment landscape is growing, it’s also getting more complex, which is why we need to evolve our approach to predictive biomarkers.

AACR Checkpoint Inhibitors TweetIO Targets Tweet - How Can We Predict What Will Work Better

Currently, immunotherapy isn’t able to help everyone. Yet scientists like our own Daniel Lieber and others are finding that some clinical markers, including tumor mutational burden (TMB), could help us enhance our understanding of which patients are most likely to respond.

AACR Tumor Mutational Burden is associated with response to immunotherapy in some indications tweetAACR tweet: Garraway: Mutational load and cytolytic activity correlate with response. Deep ecosystem understanding needed

AACR tweet: Our CSO at AACR17: New markers may help explain why some NSCLC patients w/ high TMB don’t respond to immunotherapyComprehensive genomic profiling (CGP) could help us unravel the complexity of cancer and match the right treatment to the right patients. We presented new data showing how our CGP assay FoundationOne® can identify potentially actionable mutations in several cancer types, including breast cancer.

AACR Tweet: ESR1 fusion genes found in endocrine-resistant metastatic breast cancer presented by Ryan Hartmaier

Matching patients to the right clinical trial was another robust and important conversation at the meeting. New results suggested that CGP can help accelerate clinical trials by identifying responders to a range of targeted therapies and immunotherapies.

AACR Tweet: Sequencing with NGS massively accelerated clinical trialsAACR Tweet: Cancer type and mutation identity influenced response to targeted therapy in a basket clinical trial.AACR Tweet: Rather than bringing the patient to the clinical trial bring the clinical trial to the patient.We’re proud to contribute to the fight against cancer on many fronts, including our partnership with the Blood Profiling Atlas in Cancer (BPAC). Our Chief Scientific Officer Phil Stephens participated in a panel with other BPAC members discussing considerations for using liquid biopsy in drug and diagnostic development and for opening up more treatment options.

AACR Tweet: Regulatory Considerations panel discussion at #AACR17 with #BloodPAC members

Former Vice President Joe Biden took the stage to discuss Cancer Moonshot and affirmed his ongoing commitment to this initiative and urged us all to keep making progress in cancer prevention, diagnosis and treatment. We’re proud to participate in an initiative of this scale and look forward to seeing his efforts continue through Cancer Moonshot.

AACR Tweet: "This is not the time to undercut progress. It's time to double down." -@JoeBiden re: cuts to @NIHAACR Tweet: At #AACR17, @JoeBiden spoke about the critically important bipartisan work to be done in continuing the fight against cancerAs in past years, this year’s conference was another example of the incredible work made possible through the efforts of researchers, physicians and patients around the globe. We’re honored to have been a part of #AACR17 and hope to continue transforming cancer research and inspiring new innovation.